Clinical trialUNITERAREApr 3
Researchers are testing a new drug called elritercept to see if it works better than a standard treatment (epoetin alfa) for anemia in adults with myelodysplastic syndromes (MDS)—a blood disorder where the bone marrow doesn't make enough healthy blood cells. People in this study have low, very low, or intermediate risk MDS and need regular blood transfusions. The trial is now accepting patients.
WHY IT MATTERSThis Phase 3 trial is actively recruiting adults with MDS who require transfusions, offering access to an investigational treatment that may reduce their dependence on blood transfusions.
Clinical trialUNITERAREApr 3
Researchers at Emory University are looking for pregnant women with sickle cell disease to join a study about blood transfusions. The study will test whether giving blood transfusions during pregnancy can help prevent serious complications for both the mother and baby. This is a Phase 4 trial, which means the treatment has already been tested before and researchers want to learn more about how well it works.
WHY IT MATTERSThis trial is now actively recruiting pregnant women with sickle cell disease — participation could help prevent pregnancy complications like stroke, organ damage, and miscarriage that occur at higher rates in this population.
NewsUNITERAREApr 3
The PAN Foundation's financial assistance program for phenylketonuria (PKU) — a rare genetic condition that affects how the body processes a protein called phenylalanine — is currently closed and not accepting new applications. The program previously offered up to $12,000 per year to help patients pay for treatment costs. The fund status changed on April 2, 2026.
WHY IT MATTERSIf you have PKU and were relying on this $12,000 annual assistance to afford your special diet or medications, you'll need to find alternative financial support resources immediately.
NewsUNITERAREApr 3
The PAN Foundation's financial assistance program for myasthenia gravis patients is currently closed. This program normally provides up to $12,000 per year to help patients pay for treatment costs. The fund status changed on April 2, 2026, and patients can check the PAN Foundation website for updates on when it might reopen.
WHY IT MATTERSMyasthenia gravis patients who struggle to afford medications and treatments need to know this assistance fund is temporarily unavailable and should monitor for reopening or explore alternative financial aid programs.
NewsUNITERAREApr 3
The PAN Foundation's financial assistance program for hereditary angioedema (HAE) is currently closed and is not accepting new applications. This program previously provided up to $12,000 per year to help patients afford treatment costs. The fund status changed on April 2, 2026.
WHY IT MATTERSIf you have hereditary angioedema and rely on financial assistance to afford your medications, you'll need to explore alternative funding sources since this major assistance program is temporarily unavailable.
NewsUNITERAREApr 3
The PAN Foundation's financial assistance program for Fabry disease patients is currently closed and not accepting new applications. This program previously provided up to $12,000 per year to help eligible patients pay for treatment costs. The fund status changed on April 2, 2026, and patients interested in applying should check the PAN Foundation website for updates on when it might reopen.
WHY IT MATTERSFabry disease patients who rely on financial assistance to afford expensive enzyme replacement or substrate reduction therapies have lost access to this $12,000 annual benefit, making it harder to maintain continuous treatment.
NewsUNITERAREApr 3
The PAN Foundation's financial assistance program for Pompe disease patients is currently closed and not accepting new applications. This program previously provided up to $12,000 per year to help eligible patients pay for treatment costs. The fund status changed on April 2, 2026, and patients should check the PAN Foundation website for updates on when it might reopen.
WHY IT MATTERSPompe disease patients who rely on financial assistance to afford enzyme replacement therapy or other treatments now have one fewer funding option available, which could impact their ability to access care.
NewsUNITERAREApr 3
The PAN Foundation's financial assistance fund for ALS (a disease that affects nerve cells controlling muscles) is currently closed and not accepting new applications. This fund previously provided up to $12,000 per year to help patients pay for treatment costs. The fund status changed on April 2, 2026.
WHY IT MATTERSIf you have ALS and were counting on this $12,000 annual assistance from PAN Foundation, you'll need to explore other financial resources immediately, as this fund is no longer available.
NewsUNITERAREApr 3
The PAN Foundation's financial assistance program for people with primary immunodeficiency is currently closed and not accepting new applications. Primary immunodeficiency is a group of disorders where the immune system doesn't work properly, making it harder to fight infections. When this fund was open, it could help eligible patients pay up to $12,000 per year toward treatment costs.
WHY IT MATTERSPatients with primary immunodeficiency who were relying on this $12,000 annual assistance need to immediately identify alternative funding sources, as this program is no longer accepting applications as of April 2, 2026.
NewsUNITERAREApr 3
The PAN Foundation's financial assistance program for Duchenne muscular dystrophy patients has closed as of April 2, 2026. This program previously provided up to $12,000 per year to help eligible patients pay for treatment costs. Patients who need financial help with their DMD care should contact PAN Foundation or explore other assistance programs.
WHY IT MATTERSPatients with Duchenne muscular dystrophy who were relying on this $12,000 annual benefit to afford medications or treatments now need to find alternative financial assistance sources immediately.
NewsUNITERAREApr 3
The PAN Foundation's financial assistance program for idiopathic pulmonary fibrosis (a lung disease where lung tissue becomes scarred and stiff over time) is currently closed and is not accepting new applications. This program previously offered up to $12,000 per year to help patients pay for treatment costs. The fund status changed on April 2, 2026.
WHY IT MATTERSIf you have idiopathic pulmonary fibrosis and need help paying for medications or treatment, you cannot currently apply to this specific PAN Foundation program, so you'll need to explore other financial assistance options.
NewsUNITERAREApr 3
The PAN Foundation's Multiple Sclerosis Fund, which helped patients pay for MS medications and treatments, is currently closed and not accepting new applications. The fund previously offered up to $12,000 per year in financial assistance. The status changed on April 2, 2026, so it may reopen in the future.
WHY IT MATTERSIf you have MS and were relying on this fund to help pay for your medications, you'll need to find alternative financial assistance programs immediately since this specific fund is no longer accepting applications.
NewsUNITERAREApr 3
The PAN Foundation's financial assistance fund for paroxysmal nocturnal hemoglobinuria (PNH) — a rare blood disorder where red blood cells break down too quickly — is currently closed and stopped accepting new applications as of April 2, 2026. This fund previously provided up to $12,000 per year to help patients pay for treatment costs. Patients who need financial help with their PNH medications should check the PAN Foundation website for updates on when the fund might reopen.
WHY IT MATTERSPatients with PNH who were relying on this $12,000 annual benefit to afford their medications now need to find alternative financial assistance programs immediately, as this major funding source is no longer available.
NewsUNITERAREApr 3
The PAN Foundation's financial assistance program for spinal muscular atrophy (SMA) is currently closed and is not accepting new applications. This program previously provided up to $12,000 per year to help eligible patients pay for treatment costs. The fund status changed on April 2, 2026.
WHY IT MATTERSIf you have spinal muscular atrophy and need help paying for medications like Zolgensma or Spinraza, you'll need to explore other financial assistance programs since this major funding source is temporarily unavailable.
Clinical trialUNITERAREApr 3
Researchers are looking for people with diabetes to test a new way to treat bad breath caused by gum disease. The treatment combines regular gum cleaning with a special light therapy that kills bacteria in the mouth. This study will help doctors understand if this combination works better than standard gum treatment alone.
WHY IT MATTERSIf you have diabetes and struggle with bad breath despite good oral hygiene, this trial offers access to an innovative combination treatment that may address both the gum disease and halitosis that often accompany diabetes.
Clinical trialUNITERAREApr 3
Researchers at King's College London are testing whether probiotics (helpful bacteria) can reduce skin inflammation that some people experience during perimenopause (the years leading up to menopause). This is an early-stage study to see if this approach might work before larger trials are done. The study is now accepting participants.
WHY IT MATTERSIf probiotics prove effective for perimenopause-related skin inflammation, this could offer a non-hormonal treatment option for people experiencing this symptom during the menopausal transition.
Clinical trialUNITERAREApr 3
Researchers are looking for patients who need a procedure called a transjugular intrahepatic portosystemic shunt (TIPS) to help study how blood clotting works in patients with liver disease. This trial will examine blood clotting patterns before and after the procedure to better understand how TIPS affects the body's ability to form and break down blood clots. The study is recruiting patients starting in April 2026 and is being run by hospitals in Paris.
WHY IT MATTERSThis trial is now recruiting patients undergoing TIPS placement — if you have advanced liver disease with portal hypertension and are scheduled for this procedure, you may be eligible to contribute to research that could improve how doctors manage bleeding risks in liver disease patients.
Clinical trialUNITERAREApr 3
Researchers at New York State Institute for Basic Research are testing a new treatment called transcranial direct current stimulation (tDCS) in children with autism. This treatment uses mild electrical currents applied to the scalp to potentially help with autism symptoms. The study is now accepting children to participate and will begin in April 2026.
WHY IT MATTERSThis trial offers families with autistic children a chance to explore a non-medication brain stimulation approach that may help with core autism symptoms, with enrollment actively opening at a major research institution.
Clinical trialUNITERAREApr 3
Researchers are testing a new medicine called glycerol tributyrate to see if it can help people with two rare mitochondrial diseases: MELAS (a condition that causes brain inflammation, acid buildup in the blood, and stroke-like episodes) and LHON-Plus (a condition that damages the optic nerve and causes vision loss). This is an early-stage study that will enroll patients starting in April 2026.
WHY IT MATTERSThis is the first clinical trial testing glycerol tributyrate specifically in MELAS and LHON-Plus patients, offering a potential new treatment option for these currently untreatable mitochondrial disorders.
NewsUNITERAREApr 3
The PAN Foundation's financial assistance fund for Gaucher disease patients is currently closed and is not accepting new applications. This fund previously provided up to $12,000 per year to help patients pay for treatment costs. The fund status changed on April 2, 2026.
WHY IT MATTERSIf you have Gaucher disease and were counting on this $12,000 annual assistance from PAN Foundation, you'll need to explore other financial support options immediately, as this fund is no longer available.